Abstract:Antimicrobial resistance is a global threat that if left unchecked could lead to 10 million annual mortalities by 2050. One factor contributing to the rise of multi-drug-resistant (MDR) pathogens is the reliance on traditional culture-based pathogen identification (ID) and antimicrobial susceptibility testing (AST) that typically takes several days. This delay of objective pathogen ID and AST information to inform clinical decision making results in clinicians treating patients empirically often using first-line, broad-spectrum antibiotics, contributing to the misuse/overuse of antibiotics. To combat the rise in MDR pathogens, there is a critical demand for rapid ID and AST technologies. Among the advances in ID and AST technologies in the past decade, single-cell diagnostic technologies powered by droplet microfluidics offer great promise due to their potential for high-sensitivity detection and rapid turnaround time. Our laboratory has been at the forefront of developing such technologies and applying them to diagnosing urinary tract infections (UTIs), one of the most common infections and a frequent reason for the prescription of antimicrobials. For pathogen ID, we first demonstrated the highly sensitive, amplification-free detection of single bacterial cells by confining them in picoliter-scale droplets and detection with fluorogenic peptide nucleic acid (PNA) probes that target their 16S rRNA (rRNA), a well-characterized marker for phylogenic classification. We subsequently improved the PNA probe design and enhanced detection sensitivity. For single-cell AST, we first employed a growth indicator dye and engineered an integrated device that allows us to detect growth from single bacterial cells under antibiotic exposure within 1 h, equivalent to two to three bacterial replications. To expand beyond testing a single antibiotic condition per device, a common limitation for droplet microfluidics, we developed an integrated programmable droplet microfluidic device for scalable single-cell AST. Using the scalable single-cell AST platform, we demonstrated the generation of up to 32 droplet groups in a single device with custom antibiotic titers and the capacity to scale up single-cell AST, and providing reliable pathogen categories beyond a binary call embodies a critical advance. Finally, we developed an integrated ID and AST platform. To this end, we developed a PNA probe panel that can identify nearly 90% of uropathogens and showed the quantitative detection of 16S rRNA from single bacterial cells in droplet-enabled AST after as little as 10 min of antibiotic exposure. This platform achieved both ID and AST from minimally processed urine samples in 30 min, representing one of the fastest turnaround times to date. In addition to tracing the development of our technologies, we compare them with contemporary research advances and offer our perspectives for future development, with the vision that single-cell ID and AST technologies powered by droplet microfluidics can indeed become a useful diagnostic tool for combating antimicrobial resistance.

On-chip Screening of Chemically Induced Mutant Strains and Assay of Their Metabolites by Liquid Chromatography Tandem Mass Spectrometry

Advances in Droplet-Based Microfluidic High-Throughput Screening of Engineered Strains and Enzymes Based on Ultraviolet, Visible, and Fluorescent Spectroscopy

An Integrated Microfluidic Chip-Mass Spectrometry System for Rapid Antimicrobial Resistance Analysis of Bacteria Producing Β-Lactamases

Droplet-based microfluidic platform for high-throughput screening of Streptomyces

Dual-modal Detection of Antimicrobial Susceptibility in Pathogenic Bacteria Based on the High-Throughput Microfluidic Platform

In Situ Raman Hyperspectral Analysis of Microbial Colonies for Secondary Metabolites Screening

Microfluidic Filter Device Coupled Mass Spectrometry for Rapid Bacterial Antimicrobial Resistance Analysis.

Live Biosensors for Ultrahigh-Throughput Screening of Antimicrobial Activity against Gram-Negative Bacteria

Combinatorial Screening SlipChip for Rapid Phenotypic Antimicrobial Susceptibility Testing

Open Droplet Microfluidics for Testing Multi-Drug Resistance and Antibiotic Resilience in Bacteria

Screening of Multi-Antibiotic Resistances Actinomycetes and Analysis of Their Metabolites

Droplet-based high-throughput cultivation for accurate screening of antibiotic resistant gut microbes

Development of a native-locus dual reporter system for the efficient screening of the hyper-production of natural products in Streptomyces

Application of FTIR and Metabolomics Analysis in High-Throughput Screening Strains

An Efficient High-Throughput Screening of High Gentamicin-Producing Mutants Based on Titer Determination Using an Integrated Computer-Aided Vision Technology and Machine Learning

A multiplexable assay for screening antibiotic lethality against drug-tolerant bacteria

Combating Antimicrobial Resistance via Single-Cell Diagnostic Technologies Powered by Droplet Microfluidics

Application of Physical Mutagenesis and High Throughput Screening Technology in the Selection of Probiotics

Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements

A low‐cost, high‐throughput microfluidic nano‐culture platform for functional metagenomics

Real-Time Metabolomics on Living Microorganisms Using Ambient Electrospray Ionization Flow-Probe